Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 1780Neoplasms 1500Carcinoma, Non-Small-Cell Lung 1045Prostatic Neoplasms 958Colorectal Neoplasms 882Lung Neoplasms 803Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 541Stomach Neoplasms 513Ovarian Neoplasms 508Neoplasm Metastasis 499Multiple Myeloma 494Recurrence 412Melanoma 387Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 356Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 306Endometrial Neoplasms 305Triple Negative Breast Neoplasms 299Glioblastoma 299Rectal Neoplasms 282Sarcoma 266Urinary Bladder Neoplasms 264Hematologic Neoplasms 264Colonic Neoplasms 255

Interventions

apalutamide 1Radiotherapy 1Glutamyl Aminopeptidase 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) × Clear all
NCT05649943 2025-09-03

APPROACH

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Recruiting
566 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT05956639 2023-07-21

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

The First Affiliated Hospital with Nanjing Medical University

Phase 3 Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡